The cholinergic system drives muscle contraction and plays a central role in the formation, maintenance, and repair of mammalian neuromuscular junctions (NMJs) and skeletal muscles. Because of these essential actions, much effort has been devoted to identifying primary and auxiliary modulatory components of the cholinergic system at NMJs and throughout skeletal muscles. Here, I asked if Lynx1, a GPI-anchored protein shown to modulate nAChRs in the brain, is present and affects the activity of nAChRs at NMJs. Molecular and cellular analysis revealed that Lynx1 levels increase in skeletal muscles, specifically at NMJs, during development. Its expression pattern also closely mirrors changes in cholinergic transmission in vivo and in vitro. As expected, I found by co-immunoprecipitation that Lynx1 interacts with muscle nAChRs and using electrophysiology, I show that Lynx1 desensitizes nAChRs to ACh at NMJs. These findings demonstrate that Lynx1 regulates the cholinergic system at NMJs, suggesting roles for this gene in developing and adult NMJs. To determine the role of Lynx1 at NMJs, I examined Lynx1 knockout mice at different ages. While deletion of Lynx1 has no discernable effect on developing NMJs, its absence increases the incidence of NMJs with age-related morphological features, such as fragmentation and denervation, in young adult and middle-aged mice. Loss of Lynx1 also increases the number of slow-type muscle fibers in young and middle-aged mice, another hallmark of aging. Along with these morphological changes, deletion of Lynx1 affects expression of genes associated with NMJ stability, myogenesis, and muscle atrophy in young adult and middle-aged mice. Not surprisingly, the loss of Lynx1 reduces the density and stability of nAChRs at NMJs. Because of these findings, I surmised that loss of Lynx1 would adversely affect NMJs under other physiological stressors. However, I found the opposite as the loss of Lynx1 augments the capacity of NMJs to repair damages during exercise, following injury to motor axons, and during the initial symptomatic stage of amyotrophic lateral sclerosis (ALS). Since Lynx1 modulates the activity of nAChRs, these contrasting findings likely represent the positive and negative effects of heightened cholinergic transmission on aging compared to injury and disease-afflicted NMJs. / Doctor of Philosophy / During normal aging and in neuromuscular diseases, such as amyotrophic lateral sclerosis (ALS), voluntary movement becomes compromised. This is largely due to deterioration of the synapse between motor neurons and skeletal muscles, called the neuromuscular junction (NMJ), which is responsible for voluntary movement. Signaling at the NMJ is driven by cholinergic transmission, which when dysregulated can directly result in degeneration of the NMJ, similar to that seen in both aging and ALS. Thus, it is critical to maintain proper cholinergic transmission for preservation of the NMJ. For the first time, I have characterized the role of an endogenous protein, Lynx1, in modulating cholinergic transmission at the NMJ. Lynx1 functions to dampen cholinergic activity to prevent muscles from becoming overwhelmed and fatigued. The work outlined in this dissertation proposes Lynx1 as a novel therapeutic candidate for preventing neuromuscular degeneration in conditions associated with dysregulated cholinergic transmission, such as ALS.
Identifer | oai:union.ndltd.org:VTETD/oai:vtechworks.lib.vt.edu:10919/100742 |
Date | 08 May 2019 |
Creators | Vaughan, Sydney Katherine |
Contributors | Graduate School, Valdez, Gregorio, Robitaille, Richard, Fox, Michael A., Theus, Michelle H., Gourdie, Robert G., Friedlander, Michael J. |
Publisher | Virginia Tech |
Source Sets | Virginia Tech Theses and Dissertation |
Detected Language | English |
Type | Dissertation |
Format | ETD, application/pdf |
Rights | In Copyright, http://rightsstatements.org/vocab/InC/1.0/ |
Page generated in 0.009 seconds